Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -9.29% is 91% above its 5-year average of -102.47%, near the high end of its 5-year range (-711.97%–85.42%).
96.37% above its 12-month average of -255.58%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
-9.29%
EBITDA MARGIN AVG TTM
-255.58%
EBITDA MARGIN AVG 3Y
-210.84%
EBITDA MARGIN AVG 5Y
-102.47%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+96.37%
CURRENT VS 3Y AVG
+95.59%
CURRENT VS 5Y AVG
+90.93%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
BioNTech SE
Market Cap
$24.48B
EBITDA Margin
-9.29%
TTM Avg
-255.58%
3Y Avg
-210.84%
5Y Avg
-102.47%
Market Cap
$23.85B
EBITDA Margin
24.13%
TTM Avg
25.03%
3Y Avg
27.36%
5Y Avg
27.53%
Market Cap
$25.27B
EBITDA Margin
27.93%
TTM Avg
16.21%
3Y Avg
17.95%
5Y Avg
14.24%
Market Cap
$25.83B
EBITDA Margin
19.69%
TTM Avg
19.16%
3Y Avg
18.89%
5Y Avg
21.02%
Market Cap
$26.37B
EBITDA Margin
15.75%
TTM Avg
14.53%
3Y Avg
14.10%
5Y Avg
17.90%
Market Cap
$26.34B
EBITDA Margin
30.90%
TTM Avg
31.59%
3Y Avg
31.63%
5Y Avg
30.80%
Market Cap
$21.08B
EBITDA Margin
50.36%
TTM Avg
50.37%
3Y Avg
51.80%
5Y Avg
47.75%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | $24.48B | -9.29% | -255.58% | -210.84% | -102.47% |
| West Pharmaceutical Services, Inc. (WST)vs › | $23.85B | 24.13% | 25.03% | 27.36% | 27.53% |
| Incyte Corporation (INCY)vs › | $25.27B | 27.93% | 16.21% | 17.95% | 14.24% |
| Quest Diagnostics Incorporated (DGX)vs › | $25.83B | 19.69% | 19.16% | 18.89% | 21.02% |
| Labcorp Holdings Inc. (LH)vs › | $26.37B | 15.75% | 14.53% | 14.10% | 17.90% |
| Mettler-Toledo International Inc. (MTD)vs › | $26.34B | 30.90% | 31.59% | 31.63% | 30.80% |
| STERIS plc (STE)vs › | $21.12B | 26.76% | 25.68% | 26.35% | 25.75% |
| United Therapeutics Corporation (UTHR)vs › | $21.08B | 50.36% | 50.37% | 51.80% | 47.75% |
| Medline Inc. (MDLN)vs › | $29.41B | 10.26% | 11.41% | 10.38% | 10.38% |
| Viatris Inc. (VTRS)vs › | $19.30B | 0.95% | 10.32% | 17.98% | 18.96% |
Gross Margin
71.0%
EBITDA Margin
-9.3%
Operating Margin
-22.6%
Net Margin
-63.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -645.83% |
| 2026-03-31 | -457.07% |
| 2025-12-31 | -7.49% |
| 2025-09-30 | 5.09% |
| 2025-06-30 | -172.58% |
| 2025-03-31 | -268.76% |
| 2024-12-31 | 26.39% |
| 2024-09-30 | 4.41% |
| 2024-06-30 | -711.97% |
| 2024-03-31 | -249.95% |
| 2023-12-31 | 40.91% |
| 2023-09-30 | 12.78% |
| 2023-06-30 | -316.88% |
| 2023-03-31 | 53.70% |
| 2022-12-31 | 77.65% |
| 2022-09-30 | 69.95% |
| 2022-06-30 | 70.16% |
| 2022-03-31 | 74.99% |
| 2021-12-31 | 85.42% |
| 2021-09-30 | 77.92% |
| 2021-06-30 | 79.40% |
| 2021-03-31 | 81.78% |
| 2020-12-31 | 74.32% |
| 2020-09-30 | -263.11% |
| 2020-06-30 | -172.90% |
| 2020-03-31 | -183.03% |
| 2019-12-31 | -154.12% |
| 2019-09-30 | -99.02% |
| 2019-06-30 | -153.02% |
| 2019-03-31 | -140.13% |
| 2018-12-31 | 9.14% |
| 2018-09-30 | -81.60% |
| 2018-06-30 | -48.52% |
| 2018-03-31 | -48.52% |
